Authors
Jänne, PYang, J
Kim, D
Planchard, D
Ohe, Y
Ramalingam, S
Ahn, M
Kim, S
Su, W
Horn, L
Haggstrom, D
Felip, E
Kim, J
Frewer, P
Cantarini, M
Brown, K
Dickinson, P
Ghiorghiu, S
Ranson, Malcolm R
Affiliation
Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, BostonIssue Date
2015-04-30
Metadata
Show full item recordAbstract
The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer). In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.Citation
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. 2015, 372 (18):1689-99 N Engl J MedJournal
The New England Journal of MedicineDOI
10.1056/NEJMoa1411817PubMed ID
25923549Type
ArticleLanguage
enISSN
1533-4406ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1411817